RECURRENT RECTAL CANCER COMPLICATED WITH PERFORATION AND NECROTISING FASCIITIS DURING NEOADJUVANT THERAPY
Corresponding author:
[email protected]
Accepted
28 March 2026
Available Online
15 June 2018
Abstract
INTRODUCTION: RECTAL CANCER LOCAL RECURRENCE IS LESS FREQUENT SINCE MULTIDISCIPLINARY
APPROACH HAS BEEN IMPLEMENTED, USUALLY TME EXCISION BEING PERFORMED AFTER NEOADJUVANT THERAPY. IN CASE OF RECURRENCE, NEOADJUVANT THERAPY, INCLUDING STANDARD DOSE RADIOTHERAPY SHOULD BE CONSIDERED IF NOT PERFORMED INITIALLY. PATIENTS PREVIOUSLY IRRADIATED, CAN BENEFIT OF LOWER-DOSES RE-IRRADIATION CONCOMITANT WITH CHEMOTHERAPY, FACILITATING A CURATIVE SURGICAL RESECTION.
CASE REPORT: IT IS PRESENTED THE CASE OF A 68 YEARS OLD PATIENT, WHO PERFORMED A RECTAL ANTERIOR
RESECTION WITH COLO-RECTAL ANASTOMOSIS FOR RECTAL TUMOR 4 YEARS BEFORE IN ANOTHER MEDICAL UNIT. THE PATIENT IS DIAGNOSED WITH RECURRENCE INVOLVING THE ANASTOMOSIS, FOR WHICH MULTIDISCIPLINARY TEAM RECOMMENDED RADIOCHEMOTHERAPY PRIOR TO SURGERY. DURING THE NEOADJUVANT THERAPY, BEFORE THE LAST CHEMOTHERAPY CURES THE PATIENT IS EMERGENCY SUBMITTED TO SURGERY SERVICE FOR INFLAMMATORY TUMEFACTION WITH NECROTISING FASIITIS IN THE RIGHT ISCHIORECTAL FOSSA. A FIRST SURGERY CONSISTING IN DRAINAGE AND EXTENSIVE DEBRIDEMENT ALSO OBESERVES RECTAL WALL PERFORATION. A SECOND IMMEDIATE INTERVETION CONSISTING IN A TERMINAL COLOSTOMY IS PERFORMED. AFTER ANTIBIOTHERAPY, LOCAL DRESSINGS, AND SEPTIC CONTROL OF THE WOUND AN ABDOMINO- ERINEAL SALVAGE RESECTION IS DONE, AN IMPORTANT SKIN DEFECT REMAINING.
CONCLUSION: A QUICK AND EFICCIENT MANAGEMENT OF A SEVERE CONDITION PERMITTED NOT ONLY TO CONTROL A LIFE THREATENING SITUATION , BUT ALSO PERFORMING AN ABDOMINO-PERINEAL RESECTION. A MORE OFTEN OR MAYBE ROUTINELY USE OF DIVERTING COLOSTOMY BEFORE RADIOCHEMOTHERAPY SHOULD BE CONSIDERED IN CASE OF RECURRENT RECTAL CANCER, DETAILED STUDIES BEING NECESSARY ON THIS ASPECT
Keywords
RECTUM
CANCER
RECURRENCE
PERFORATION
RADIOCHEMOTHERAPY
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Braendengen M, Tveit KM, Berglund A et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687–3694.
[2]
Bujko K, Wyrwicz L, Rutkowski A et al. Long -course oxaliplatin -based preoperative chemoradiation versus 5 x5Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 2016; 27: 834–842.
[3]
Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemo radiation. Lancet 2002;360:307–8
[4]
Franke, J, Rosenzweig, S, Reinartz, P et al, Value of positron emission tomography (18F -FDG-PET) in the diagnosis of recurrent rectal cancer. Chirurg. 2000;71:80–85 Glynne-Jones R. et all. Rectal cancer: ESMO Clinical Practi ce Guineline for diagnosis, treatment and follow -up, Annals of Oncology 28 (Supplement 4):iv22-iv40, 2017
[5]
Guren MG, Undseth C, Rekstad BL et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol 2014; 113: 151–157.
[6]
Huh JW . Curative potential of surgical resection for locally recurrent rectal cancer. Ann Surg . 2014 Jun;259(6):e88.
[7]
Kaiser AM. Diversion with neoadjuvant vs surgery with adjuvant treatment for obstructing rectal cancer? Dis Colon Rectum. 2012 Oct;55(10):e346
[8]
Kim DJ , Kim JH, Lim JS, et al. Restaging of rectal cancer with MRI imaging after concurrent chemotherapy and radiation therapy. Radio Graphics 2010;30:503 –16
[9]
National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Rectal Cancer, Version 4.2017 -- January 18, 2018. Accessed at www.nccn.org/professionals/physician_gls/pdf/rectal.pdf on February 8, 2018
[10]
Patel JA, Fleshman JW, Hunt SR, Safar B, Birnbaum EH, Lin AY, Mutch MG. Is an elective diverting colostomy warranted in patients with an endoscopically obstructing rectal cancer before neoadjuvant chemotherapy? Dis Colon Rectum. 2012 Mar;55(3):249-55
[11]
Rania A . Marouf, Mary Y. Tadros , Tarek Y. Ahmed. Value of diffusion -weighted MR imaging in assessing response of neoadjuvant chemo and radiation therapy in locally advanced rectal cancer. The Egyptian Journal of Radiology and Nuclear Medicine . Volume 46, Issue 3, September 2015, Pages 553 –
[12]
National Comprehensive Cancer Network, Clini cal Practice Guidelines in Oncology (NCCN Guidelines®), Rectal Cancer, Version 4.2017 -- January 18, 2018. Accessed at www.nccn.org/professionals/physician_gls/pdf/rectal.pdf on February 8, 2018
[13]
Salerno G , Sinnatamby C, Branagan G, et al. Defining the rect um: surgically, radiologically and anatomically. Colorectal Dis. 2006;8 Suppl 3:5–9
[14]
Sebag-Montefiore, D, Stephens, RJ, Steele, R et al, M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 a nd NCIC-CTG CO 16): a multicentre, randomised trial. Lancet. 2009;373:811–820.
[15]
Selvaggi F, Fucini C, Pellino G, Sciaudone G, Maretto I, Mondi I, Bartolini N, Caminati F, Pucciarelli S. Outcome and prognostic factors of local recurrent rectal cancer: a pooled analysis of 150 patients. T ech Coloproctol. 2015 Mar;19(3):135-44. doi: 10.1007/s10151-014-1241-x. Epub 2014 Nov 11.
[16]
Shimada A, Nakamura T, Ishii M, Chiba N, Ishikawa S, Arisawa Y, Hashimoto M. A case of necrotizing fasciitis developed in a patient with recurrent rectal cancer treated with chemotherapy [Article in Japanese] Gan To Kagaku Ryoho. 2013 May;40(5):663-5.
[17]
van den Brink M, Stiggelbout AM, van den Hout WB et al, Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22:3958–3964.
[18]
Wiggers T. Management of local recurrence of rectal cancer. European Journal of Cancer , September 2011, Volume 47, Supplement 3, Pages S290–S291